Skip to main content
Premium Trial:

Request an Annual Quote

Some Unused

Nearly a quarter of rapid antigen tests the US bought have gone unused, the Wall Street Journal reports.

In late September, former President Donald Trump announced the purchase of 150 million rapid, point-of-care SARS-CoV-2 antigen tests from Abbott Laboratories. At the time, 360Dx reported that about a third of the tests — company's BinaxNOW COVID-19 Ag Card — were to go to nursing homes, assisted living facilities, and hospice care agencies and most were to go to the states, in part to help schools reopen.

But according to the Journal, concerns regarding the test's accuracy as well as logistical matters have limited its use. It reports that 32 million of the tests given to the states have not been used, in line with a December report from the Department of Health and Human Services that found 20 states still had half or more of the tests they had been given. The Journal adds that some state officials tell it there were concerns about how to roll the test out, as they are best at identifying infectious individuals and when used repeatedly on the same population, and some schools haven't adopted the tests due to the training required.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.